title: Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.
abstract: The purpose of this study was to determine whether docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma. Chemotherapy-naïve or previously treated patients (one regimen) with histopathologically documented endometrial carcinoma and Eastern Cooperative Oncology Group performance status </=2 entered the study. Docetaxel 70 mg m(-2) was administered intravenously on day 1 of a 3-week cycle up to a maximum of six cycles. If patients responded well to docetaxel, additional cycles were administered until progressive disease or unacceptable toxicity occurred. Of 33 patients with a median age of 59 years (range, 39-74 years) who entered the study, 14 patients (42%) had received one prior chemotherapy regimen. In all, 32 patients were evaluable for efficacy, yielding an overall response rate of 31% (95% confidence interval, 16.1-50.0%); complete response and partial response (PR) were 3 and 28%, respectively. Of 13 pretreated patients, three (23%) had a PR. The median duration of response was 1.8 months. The median time to progression was 3.9 months. The predominant toxicity was grade 3-4 neutropenia, occurring in 94% of the patients, although febrile neutropenia arose in 9% of the patients. Oedema was mild and infrequent. Docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma, including those previously treated with chemotherapy; however, the effect was transient and accompanied by pronounced neutropenia in most patients.
authors.affiliation: Department of Medical Oncology, National Cancer Center Hospital, 104-0045 Tokyo, Japan. nkatsuma@ncc.go.jp
authors.forename: N
authors.initials: N
authors.lastname: Katsumata
authors.forename: K
authors.initials: K
authors.lastname: Noda
authors.forename: S
authors.initials: S
authors.lastname: Nozawa
authors.forename: R
authors.initials: R
authors.lastname: Kitagawa
authors.forename: R
authors.initials: R
authors.lastname: Nishimura
authors.forename: S
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: D
authors.initials: D
authors.lastname: Aoki
authors.forename: N
authors.initials: N
authors.lastname: Susumu
authors.forename: H
authors.initials: H
authors.lastname: Kuramoto
authors.forename: T
authors.initials: T
authors.lastname: Jobo
authors.forename: K
authors.initials: K
authors.lastname: Ueki
authors.forename: M
authors.initials: M
authors.lastname: Ueki
authors.forename: I
authors.initials: I
authors.lastname: Kohno
authors.forename: K
authors.initials: K
authors.lastname: Fujiwara
authors.forename: Y
authors.initials: Y
authors.lastname: Sohda
authors.forename: F
authors.initials: F
authors.lastname: Eguchi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D000231:Adenocarcinoma, Papillary / Q000188:drug therapy / Q000401:mortality / Q000556:secondary; D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000401:mortality / Q000556:secondary; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000401:mortality / Q000556:secondary; D000077143:Docetaxel; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D007564:Japan; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D016879:Salvage Therapy; D015996:Survival Rate; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel